- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Coaching Changes
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
re: Akebia Therapeutics (AKBA)- Vadadustat FDA Approved AT LAST!!
Posted on 2/25/21 at 11:40 am to PhiTiger1764
Posted on 2/25/21 at 11:40 am to PhiTiger1764
I’m back in at 3.49/share
1
Posted on 2/25/21 at 11:52 am to WDE24
I hopped on it at 3.54.
I'm assuming this is a long play.
I'm assuming this is a long play.
Posted on 2/25/21 at 12:28 pm to Lieutenant Dan
Waited and got in at 3.57
Posted on 2/26/21 at 8:07 am to Louie
It’s 3.31 premarket. A very good entry point IMO for anyone interested.
This post was edited on 2/26/21 at 8:13 am
Posted on 2/26/21 at 8:24 am to WDE24
Bought a bit more here. Like someone else said early on. Allah Akba!!
Posted on 2/26/21 at 2:49 pm to bayoubengals88
Looks like a good stock to invest in!
Posted on 2/26/21 at 3:48 pm to Lieutenant Dan
quote:
hopped on it at 3.54.
I'm assuming this is a long play.
Yes, the nda is behind schedule was the latest I heard
Posted on 2/27/21 at 10:52 am to oklahogjr
quote:
hopped on it at 3.54.
I'm assuming this is a long play.
Yes, the nda is behind schedule was the latest I heard
I was able to add another 200 shares @ 3.29...getting my basis down to 3.32 on 508 shares.
What's going on with the nda?
Posted on 2/27/21 at 12:38 pm to Vols&Shaft83
quote:Expected during second quarter
What's going on with the nda?
Posted on 3/1/21 at 11:48 am to WDE24
One of the few red ones today, but I'd rather be buying a stock that isn't ripping today.
Posted on 3/1/21 at 1:04 pm to GeneralLee
Just bought a few $2.50 October calls. Seems to be minimal risk with some good upside
Posted on 3/1/21 at 5:25 pm to itsbigmikey
Damn. They missed earnings by $.20
That can’t be good
That can’t be good
Posted on 3/1/21 at 5:35 pm to BigOrangeBri
quote:
Damn. They missed earnings by $.20
That can’t be good
Welcome to last week, Bri
Posted on 3/1/21 at 6:29 pm to Vols&Shaft83
quote:
Welcome to last week, Bri
I hold a decent amount and had no clue. Just happened to glance at it today. Guess I should pay a little more attention lol.
Posted on 3/1/21 at 7:40 pm to bayoubengals88
What do you see as the upside potential here if the NDA is filed? Flipped this from $3.5 to $4.3 a few weeks ago and bought back in at $3.35 but concerned that we might be nowhere near the bottom if the NDA is months away, given their earnings disaster on the recent call.
Posted on 3/1/21 at 9:02 pm to GeneralLee
I sold. I basically got out no harm no could not much made or lost.
I don't like companies who continually disappoint. Makes it very hard on the wallet
I don't like companies who continually disappoint. Makes it very hard on the wallet
Posted on 3/1/21 at 9:06 pm to oklahogjr
I’m getting out first chance I get as well.
Posted on 3/2/21 at 10:37 am to Lieutenant Dan
I figured I would try this out. Put a little into it...43 shares at $3.44
Posted on 3/2/21 at 11:17 am to GeneralLee
quote:No guesses. I like it in the 3s for a 2-3 year play. Not looking for 15%
What do you see as the upside potential here if the NDA is filed?
Made 40% and didn't sell. Don't care. Long term investment.
Not much money in it at all. Yet.
Posted on 3/31/21 at 9:59 am to bayoubengals88
They submitted their NDA yesterday, so we're seeing a bump today. Not sure of a PDUFA date, if one exists. Having gotten burned on AUPH thus far, I'm thinking this could be one where I look to exit my position with some gains before the action date (assuming of course, I have gains to take).
quote:
In the wings and poised to reshape the treatment landscape for hematologic disorders are two potential blockbuster drugs - Valrox (valoctocogene roxaparvovec) for hemophilia A and vadadustat for anemia related to chronic kidney disease - that are among the 11 included in the Cortellis Drugs to Watch analysis predicted to achieve annual sales of $1 billion by 2024.
quote:
Several HIF-PH enzyme inhibitors are currently in development targeting the estimated $3.5 billion renal anemia market, including Cambridge, Mass.-based Akebia Therapeutics Inc.’s vadadustat, which has advanced to late-stage clinical trials. In July, its strategic partner, Osaka-based Mitsubishi Tanabe Pharma Corp., filed an NDA with the Japanese Ministry of Health, Labour and Welfare, seeking approval for the product as a treatment for anemia due to CKD.
The filing is based on data from four studies in Japanese patients: an active-controlled study in non-dialysis-dependent CKD anemia (J01), another active-controlled study but in dialysis-dependent patients with CKD anemia (J03), and two single-arm studies in patients with peritoneal and hemodialysis-dependent CKD anemia (J02 and J04). Vadadustat demonstrated non-inferiority with respect to hemoglobin level versus the active comparator (darbepoetin alfa) in both dialysis- and non-dialysis-dependent patients (J01 and J03 studies; 11.66 vs 11.93 g/dL, and 10.61 vs 10.65 g/dL, respectively) and showed therapeutic effect in the single-arm studies.
If approved, the company expects commercial launch during mid-2020, and filings in the U.S. and the EU are planned, those territories covered by Akebia’s alliance with Otsuka Pharmaceutical Co., Ltd.
This post was edited on 3/31/21 at 10:27 am
Page 4 of 29
Popular
Back to top
Follow TigerDroppings for LSU Football News